1,1,1,2-Tetrafluoroethane
Showing 1 - 25 of >10,000
Abscess Trial in Philadelphia (Lidocaine, Vapocoolant)
Terminated
- Abscess
-
Philadelphia, PennsylvaniaAlbert Einstein Medical Center
Mar 6, 2020
Cachexia Trial in Ruddington (Part 1 Group 1 (ACM-001.1and Pindolol and Placebo), Part 1 Group 2 (Pindolol), Part 2 Group D
Completed
- Cachexia
- Part 1 Group 1 (ACM-001.1and Pindolol and Placebo)
- +5 more
-
Ruddington, United KingdomQuotient Sciences Ltd
Aug 31, 2023
NSCLC, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1) Trial (MK-2870, Pembrolizumab, Carboplatin)
Not yet recruiting
- Non-small Cell Lung Cancer
- +4 more
- MK-2870
- +2 more
- (no location specified)
Sep 15, 2023
CYP1A2, ABCB1, CYP2C9 and Plasma Concentration of Agomelatine in
Not yet recruiting
- Polymorphism, Genetic
- +5 more
- (no location specified)
Nov 3, 2023
Long-Term Development of Muscular Dystrophy Outcome Assessments
Not yet recruiting
- LGMD1A
- +33 more
-
Richmond, VirginiaVirginia Commonwealth University
Aug 3, 2023
Alopecia Areata Trial in Sohag (Janus Kinase 1 and 2)
Recruiting
- Alopecia Areata
- Janus Kinase 1 and 2
-
Sohag, EgyptSohag University hospitals
May 12, 2023
Myotonic Dystrophy 1 Trial (ARO-DM1 for Injection, Placebo)
Not yet recruiting
- Myotonic Dystrophy 1
- ARO-DM1 for Injection
- Placebo
- (no location specified)
Nov 14, 2023
Esophageal Squamous Carcinoma, HER-2 Protein Overexpression Trial (RC48+PD-1+platinum-based)
Not yet recruiting
- Esophageal Squamous Carcinoma
- HER-2 Protein Overexpression
- (no location specified)
Sep 24, 2023
Fatigue, Energy Trial in Del Mar (Energy Placebo Control Form 1, Energy Active Study Product 1.1 Usage, Energy Active Study
Recruiting
- Fatigue
- Energy
- Energy Placebo Control Form 1
- +3 more
-
Del Mar, CaliforniaRadicle Science, Inc
Oct 3, 2023
Treatment of Symptoms of Grade 2 and Grade 3 Late Xerostomia From Salivary Gland Hypofunction Caused by Radiotherapy for Cancer
Recruiting
- Treatment of Symptoms of Grade 2 and Grade 3 Late Xerostomia From Salivary Gland Hypofunction Caused by Radiotherapy for Cancer of the Oropharynx
- AAV2-hAQP1 Concentration 1
- +2 more
-
Charlotte, North CarolinaAtrium Health
Jun 22, 2023
People Who Have Genetic Changes and Features of Autism: Simons
Recruiting
- 16P11.2 Deletion Syndrome
- +184 more
-
New York, New York
- +1 more
Jan 6, 2023
Glucagon-like Peptide-1 Receptor Agonists According to Type 2
Recruiting
- Diabetes Mellitus, Type 2
- GLP-1 receptor agonist
-
Bari, ItalyAzienda Ospedaliero-Universitaria Policlinico Bari
Nov 4, 2023
Periodontitis, Diabetes Trial in Rawalpindi (1ml of 1% metronidazole gel, 1ml of 2% minocycline gel, 1ml of combination of 1%
Completed
- Periodontitis
- Diabetes Mellitus
- 1ml of 1% metronidazole gel
- +2 more
-
Rawalpindi, Punjab, PakistanIslamic International Medical Collège, IIMC
Aug 31, 2023
Covid19 Trial in Cypress (VXA-CoV2-1)
Completed
- Covid19
- VXA-CoV2-1
-
Cypress, CaliforniaWCCT
Jan 17, 2023
Type 1 Diabetes, Type 2 Diabetes Trial in Tunbridge Wells (Four Week Self-Compassion Course)
Not yet recruiting
- Type 1 Diabetes
- Type 2 Diabetes
- Four Week Self-Compassion Course
-
Tunbridge Wells, United KingdomSalomons Institute for Applied Psychology, Canterbury Christ Chu
Mar 1, 2023
Measurement Information System-29 v2.1 for Postpartum Women
Not yet recruiting
- Well-Being, Psychological
- PROMIS-29 v2.1 (Patient-Reported Outcomes Measurement Information System)
- +2 more
-
Toronto, Ontario, CanadaMount Sinai Hospital
Aug 16, 2023
Solid Tumors, Adult Trial in Dallas, Hangzhou (HF158K1 /Arm 2 mg/m², HF158K1 /Arm 6 mg/m², HF158K1 /Arm 15 mg/m²)
Not yet recruiting
- Solid Tumors, Adult
- HF158K1 /Arm 2 mg/m²
- +5 more
-
Dallas, Texas
- +2 more
May 6, 2023
Poliomyelitis Trial in Dhaka (Novel oral poliomyelitis vaccine type 1 (nOPV1), Novel oral poliomyelitis vaccine type 2 (nOPV2),
Not yet recruiting
- Poliomyelitis
- Novel oral poliomyelitis vaccine type 1 (nOPV1)
- +3 more
-
Dhaka, BangladeshInternational Centre for Diarrhoeal Disease Research
Nov 14, 2023
Triple-negative Breast Cancer Trial in Shanghai (A1: SHR-A1811, A2: SHR-A1811 with Camrelizumab, B1: TROP2 ADC)
Not yet recruiting
- Triple-negative Breast Cancer
- A1: SHR-A1811
- +11 more
-
Shanghai, ChinaFudan University Shanghai Cancer Center
Feb 19, 2023
Diabetes, Type 2, Diabetes, Type 1, Gastroparesis With Diabetes Trial in Cleveland (FreeStyle Libre 3 continuous glucose
Not yet recruiting
- Diabetes Mellitus, Type 2
- +2 more
- FreeStyle Libre 3 continuous glucose monitoring sensor
-
Cleveland, OhioCleveland Clinic Foundation
Sep 6, 2023
Metastatic Colorectal Cancer Trial (LB-100, Azenosertib)
Not yet recruiting
- Metastatic Colorectal Cancer
- (no location specified)
Oct 31, 2023
Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)
Recruiting
- Biliary Tract Cancer
- +2 more
-
Shanghai, ChinaZhongshan hospital, Fudan University
Aug 12, 2023
Ultra-rapid BRCA1/2 Status Screening Test in Theranostic
Not yet recruiting
- Breast Cancer
- Questionnaires
- Communication of the results of the BRCA1/2 ultra rapid test
- (no location specified)
Oct 26, 2023
Vaccine Reaction Trial in Bengaluru (Regimen 1, Regimen 2)
Recruiting
- Vaccine Reaction
- Regimen 1
- Regimen 2
-
Bengaluru, Karnataka, IndiaKempegowda Institute Of Medical Sciences Hospital and Research C
Oct 4, 2023